ResearcherNational Cancer CenterActive in the last 2 years
Min Kyeong Kim
Matched on ORCID iD 0000-0002-0349-0194; OpenAlex author ID A5101874068. Sources: OpenAlex.
Their work
- Papers
- 6 (first author 2, last author 0)
- Trials
- 0
- Grants
- 0
- Labs led
- 0
- Collaborators
- 19
2017: 1 paper · 2018: 1 paper · 2019: 1 paper · 2020: none · 2021: 1 paper · 2022: none · 2023: none · 2024: 1 paper · 2025: 1 paper
Papers 6
- Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic Adenocarcinoma: A Prospective Multicente… Co-author DOI 10.1093/clinchem/hvaf066↗
- Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. Co-author DOI 10.1111/cas.16104↗
- Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohort Study. First author DOI 10.3390/cancers13215466↗
- Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Model System Using Percutaneous Biopsy Sam… Co-author DOI 10.3389/fonc.2019.00875↗
- Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal Adenocarcinoma. Co-author DOI 10.1373/clinchem.2017.283721↗
- Induction Chemotherapy with Gemcitabine and Cisplatin Followed by Simultaneous Integrated Boost-Intensity Modulated Radiotherapy with Concurrent Gemcitabine fo… First author DOI 10.4143/crt.2016.495↗
Closest collaborators
The 19 strongest of 19 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.
- Sung‐Sik Han · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Woo Jin Lee · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Sang‐Jae Park · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Sun‐Young Kong · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Yun‐Hee Kim · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Sang Myung Woo · 6 shared papers, 2017–2025 · strength 0.73
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Kyong‐Ah Yoon · 5 shared papers, 2017–2024 · strength 0.51
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Paper Prognostic Implications of Multiplex Detection of KRAS Mutations in Cell-Free DNA from Patients with Pancreatic Ductal … DOI 10.1373/clinchem.2017.283721↗
- Jung Won Chun · 2 shared papers, 2024–2025 · strength 0.41
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Jin‐Hyeok Hwang · 2 shared papers, 2021–2025 · strength 0.33
- Paper Optimal Value of Mutant KRAS Circulating Tumor DNA for Predicting Prognosis and Monitoring in Patients with Pancreatic … DOI 10.1093/clinchem/hvaf066↗
- Paper Genomic Instability of Circulating Tumor DNA as a Prognostic Marker for Pancreatic Cancer Survival: A Prospective Cohor… DOI 10.3390/cancers13215466↗
- Sung Yong Choi · 2 shared papers, 2019–2024 · strength 0.27
- Paper Application of plasma circulating KRAS mutations as a predictive biomarker for targeted treatment of pancreatic cancer. DOI 10.1111/cas.16104↗
- Paper Development of Patient-Derived Preclinical Platform for Metastatic Pancreatic Cancer: PDOX and a Subsequent Organoid Mo… DOI 10.3389/fonc.2019.00875↗
- Eui Joo Kim · 1 shared paper, 2025 · strength 0.22
- Min Kyu Jung · 1 shared paper, 2025 · strength 0.22
- Dong‐Won Ahn · 1 shared paper, 2025 · strength 0.22
- Sang Hyub Lee · 1 shared paper, 2025 · strength 0.22
- Mi Rim Lee · 1 shared paper, 2024 · strength 0.19
- Jae Hee Cho · 1 shared paper, 2021 · strength 0.11
- Yu‐Sun Lee · 1 shared paper, 2019 · strength 0.08
- Eun Kyung Hong · 1 shared paper, 2017 · strength 0.06
- Tae Hyun Kim · 1 shared paper, 2017 · strength 0.06
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.